BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Innovations | Jul 25, 2019
Tools & Techniques

New CRISPR case to finally settle the score

The latest CRISPR patent case aims to do what the first didn’t: determine who gets rights to the gene editing technology in eukaryotic cells, a category that covers almost all the cell types that matter...
BC Week In Review | Nov 30, 2018
Financial News

ViaCyte attracts crossover investors for $80M series D

ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies. ViaCyte President and CEO Paul Laikind declined to disclose the triggers...
BC Extra | Nov 29, 2018
Financial News

ViaCyte attracts crossover investors for $80M series D

ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies. ViaCyte President and CEO Paul Laikind declined to disclose the triggers...
BC Innovations | Oct 4, 2018
Tools & Techniques

No crisp upper hand in CRISPR

While the most recent ruling in the ongoing CRISPR IP battle maintained the Broad Institute’s dominant patent position in the U.S., University of California Berkeley’s dominant position in Europe, coupled with the looming possibility of...
BC Week In Review | Sep 28, 2018
Financial News

CRISPR, Viking, Fate, Molecular Templates price follow-ons

CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each priced follow-ons late on Sept. 20, raising a total of $545.9 million. CRISPR raised $200 million through...
BC Week In Review | Sep 21, 2018
Company News

CRISPR partners with ViaCyte to develop immune-evasive pancreatic cells

CRISPR Therapeutics AG (NASDAQ:CRSP) and ViaCyte Inc. (San Diego, Calif.) partnered to develop a gene edited immune-evasive pancreatic stem cell line as an islet cell replacement therapy that would not require immunosuppression and could potentially...
BC Extra | Sep 21, 2018
Financial News

Follow-on roundup: CRISPR, Viking, Fate, Molecular Templates

CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each priced follow-ons late Thursday, raising a total of $545.9 million. CRISPR raised $200 million through the sale...
BC Extra | Sep 17, 2018
Company News

CRISPR partners with ViaCyte to develop immune-evasive pancreatic cells

CRISPR Therapeutics AG (NASDAQ:CRSP) and ViaCyte Inc. (San Diego, Calif.) partnered to develop a gene edited immune-evasive pancreatic stem cell line as an islet cell replacement therapy that would not require immunosuppression and could potentially...
BC Extra | Sep 28, 2017
Company News

CIRM names CEO, funds additional clinics and trials

California Institute for Regenerative Medicine named Maria Millan CEO and president. She was interim CEO and president and VP of therapeutics, and will succeed President Randal Mills, who left in June. CIRM also said it...
Items per page:
1 - 10 of 79
BC Extra | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and...
BC Innovations | Jul 25, 2019
Tools & Techniques

New CRISPR case to finally settle the score

The latest CRISPR patent case aims to do what the first didn’t: determine who gets rights to the gene editing technology in eukaryotic cells, a category that covers almost all the cell types that matter...
BC Week In Review | Nov 30, 2018
Financial News

ViaCyte attracts crossover investors for $80M series D

ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies. ViaCyte President and CEO Paul Laikind declined to disclose the triggers...
BC Extra | Nov 29, 2018
Financial News

ViaCyte attracts crossover investors for $80M series D

ViaCyte Inc. (San Diego, Calif.) announced an $80 million tranched series D round to fund development of its Type I diabetes stem cell therapies. ViaCyte President and CEO Paul Laikind declined to disclose the triggers...
BC Innovations | Oct 4, 2018
Tools & Techniques

No crisp upper hand in CRISPR

While the most recent ruling in the ongoing CRISPR IP battle maintained the Broad Institute’s dominant patent position in the U.S., University of California Berkeley’s dominant position in Europe, coupled with the looming possibility of...
BC Week In Review | Sep 28, 2018
Financial News

CRISPR, Viking, Fate, Molecular Templates price follow-ons

CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each priced follow-ons late on Sept. 20, raising a total of $545.9 million. CRISPR raised $200 million through...
BC Week In Review | Sep 21, 2018
Company News

CRISPR partners with ViaCyte to develop immune-evasive pancreatic cells

CRISPR Therapeutics AG (NASDAQ:CRSP) and ViaCyte Inc. (San Diego, Calif.) partnered to develop a gene edited immune-evasive pancreatic stem cell line as an islet cell replacement therapy that would not require immunosuppression and could potentially...
BC Extra | Sep 21, 2018
Financial News

Follow-on roundup: CRISPR, Viking, Fate, Molecular Templates

CRISPR Therapeutics AG (NASDAQ:CRSP), Viking Therapeutics Inc. (NASDAQ:VKTX), Fate Therapeutics Inc. (NASDAQ:FATE) and Molecular Templates Inc. (NASDAQ:MTEM) each priced follow-ons late Thursday, raising a total of $545.9 million. CRISPR raised $200 million through the sale...
BC Extra | Sep 17, 2018
Company News

CRISPR partners with ViaCyte to develop immune-evasive pancreatic cells

CRISPR Therapeutics AG (NASDAQ:CRSP) and ViaCyte Inc. (San Diego, Calif.) partnered to develop a gene edited immune-evasive pancreatic stem cell line as an islet cell replacement therapy that would not require immunosuppression and could potentially...
BC Extra | Sep 28, 2017
Company News

CIRM names CEO, funds additional clinics and trials

California Institute for Regenerative Medicine named Maria Millan CEO and president. She was interim CEO and president and VP of therapeutics, and will succeed President Randal Mills, who left in June. CIRM also said it...
Items per page:
1 - 10 of 79